MDT

96.83

-2.02%↓

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

Home・Aandelen Lijst・Celldex Therapeutics Inc

Celldex Therapeutics Inc

Gesloten

SectorGezondheidszorg

25.59 0.27

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

25.54

Max

26.12

Belangrijke statistieken
By Trading Economics
Inkomsten	-10M -67M
Winstmarge	-7,753.425
Werknemers	186
EBITDA	-9.8M -73M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+108.81% upside

Dividenden
By Dow Jones
Volgende Winsten	25 feb 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	200M 1.7B
Vorige openingsprijs	25.32
Vorige sluitingsprijs	25.59

Nieuwssentiment

By Acuity

50%

159 / 361 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bullish Evidence

18.91 / 20.63 Steun & Weerstand

Celldex Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

16 jan 2026, 23:29 UTC

Populaire aandelen

Stocks to Watch: Atossa Therapeutics, Union Pacific

16 jan 2026, 22:48 UTC

Acquisities, Fusies, Overnames

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- 2nd Update

16 jan 2026, 22:43 UTC

Acquisities, Fusies, Overnames

Union Pacific: Additional Information Requested to Be Provided to Surface Transportation Board

16 jan 2026, 22:22 UTC

Acquisities, Fusies, Overnames

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- Update

16 jan 2026, 21:50 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Tech, Media & Telecom Roundup: Market Talk

16 jan 2026, 21:50 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Auto & Transport Roundup: Market Talk

16 jan 2026, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

16 jan 2026, 21:50 UTC

Marktinformatie

Health Care Roundup: Market Talk

16 jan 2026, 21:48 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Union Pacific, Norfolk Southern Market Share Ruled as Faulty -- Market Talk

16 jan 2026, 21:41 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Union Pacific, Norfolk Southern Deal Rejection Leaves Questions -- Market Talk

16 jan 2026, 21:38 UTC

Acquisities, Fusies, Overnames

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- WSJ

16 jan 2026, 21:30 UTC

Acquisities, Fusies, Overnames

STB: Union Pacific, Norfolk Southern Application Doesn't Include 'Projected Market Shares' as Required

16 jan 2026, 21:30 UTC

Acquisities, Fusies, Overnames

STB: Union Pacific, Norfolk Southern Application Doesn't Include Certain Schedules, Documents Expressly Made Part of Merger Agreement

16 jan 2026, 21:30 UTC

Acquisities, Fusies, Overnames

STB: Union Pacific, Norfolk Southern Application Doesn't Contain Certain Information Required by Regulations

16 jan 2026, 21:30 UTC

Acquisities, Fusies, Overnames

STB: Application Rejected Without Prejudice to Union Pacific, Norfolk Southern Refiling Revised Application Remedying Deficiencies

16 jan 2026, 21:30 UTC

Acquisities, Fusies, Overnames

Surface Transportation Board: Union Pacific, Norfolk Southern Major Merger Application Filed Dec. 19 Incomplete

16 jan 2026, 20:44 UTC

Winsten

5 Takeaways From This Season's Wealth Management Earnings -- Barrons.com

16 jan 2026, 20:42 UTC

Marktinformatie

Oil Futures Post Fourth Straight Weekly Gain -- Market Talk

16 jan 2026, 20:28 UTC

Marktinformatie

U.S. Natural Gas Slips Ahead of Long Weekend -- Market Talk

16 jan 2026, 19:12 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Netflix Could Comment on Structure of Warner Bid During 4Q Results -- Market Talk

16 jan 2026, 18:53 UTC

Marktinformatie

Global Crude Supply Enough to Absorb Any Iran Disruption -- Market Talk

16 jan 2026, 18:41 UTC

Marktinformatie

Netflix's Ad Business Seen as Primary Revenue Driver in 2026 -- Market Talk

16 jan 2026, 18:31 UTC

Marktinformatie

U.S. Oil Rig Count Rises By 1 to 410 -- Market Talk

16 jan 2026, 17:20 UTC

Marktinformatie

Financial Services Roundup: Market Talk

16 jan 2026, 17:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

16 jan 2026, 17:20 UTC

Marktinformatie

Health Care Roundup: Market Talk

16 jan 2026, 17:03 UTC

Marktinformatie

Global Equities Roundup: Market Talk

16 jan 2026, 17:03 UTC

Marktinformatie

All Eyes on Guidance for European Big Pharma Earnings Season -- Market Talk

16 jan 2026, 16:32 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Sanofi Needs Dealmaking to Offset Pipeline Disappointments -- Market Talk

16 jan 2026, 16:20 UTC

Marktinformatie

Global Equities Roundup: Market Talk

Peer Vergelijking

Prijswijziging

Celldex Therapeutics Inc Prognose

Koersdoel

By TipRanks

108.81% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 55 USD 108.81%

Hoogste 90 USD

Laagste 24 USD

Gebaseerd op 10 Wall Street-analisten die 12-maands prijsdoelen bieden voor Celldex Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

10 ratings

Buy

Hold

Sell

Gebaseerd op 10 analisten die aandelenratings hebben gegeven aan Celldex Therapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

18.91 / 20.63Steun & Weerstand

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

159 / 361 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.